Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NRT more effective than placebo

This article was originally published in The Tan Sheet

Executive Summary

Nicotine replacement therapy helps smokers quit and abstain more effectively than a placebo, according to a meta-analysis published online April 2 by the British Medical Journal. A review of seven randomized, placebo-controlled trials of NRT use shows 6.75 percent of smokers using NRT abstained from smoking for six months - twice the rate of smokers using a placebo. Researchers led by David Moore at the School of Health and Population Sciences at the University of Birmingham added that 8.7 percent of study participants tolerated NRT with no adverse effects except some nausea. NRT marketers cite smokers' greater chances of successfully quitting in advertising for the products (see related story)
Advertisement

Related Content

Cigarette Tax Hike Sparks NRT Marketing Opportunities
Cigarette Tax Hike Sparks NRT Marketing Opportunities

Topics

Advertisement
UsernamePublicRestriction

Register

PS102782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel